Skip to content
★ Sign in to follow
Supriya Lifescience Limited logo

Supriya Lifescience Limited Stock: price and insider trades · India

IN·Mcap ₹69.8BHealth Care

No insider purchase over the last 90 days. The latest, by Shivani Satish Wagh, was filed 27 Feb 2024.

Supriya Lifescience Limited: what insiders have been doing

Every trade that managers of Supriya Lifescience Limited disclose to SEBI (PIT + SAST) is tracked on this page. The company sits in the Health Care sector. The past year has been quiet: not a single insider filing for Supriya Lifescience Limited. The previous disclosure was published on 27 February 2024.

For comparison within the same sector, see the insider buying recorded at Relmada Therapeutics, Inc. and MAIA Biotechnology, Inc. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.

Insider Decl.
8
Thresholds
n/a
Buy Volume
€101,375
7 ops. · all time
Sell Volume
n/a
1 ops. · all time

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 7,895 of 26,897 companies
61.9
score / 100
Value
37
Quality
87
FCF yld0.5%
Earn yld3.0%
EV/EBITDA23.1x
ROE19%
Gross mgn55%
Net mgn26%
Debt/EBITDA0.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹867.00
Analyst consensus
2 analysts
1.50/5
₹850.00Target ₹940.00(+8%)₹1,030.00
Income statement
Revenue₹8.3B
Gross profit₹5.7B69% margin
EBITDA₹3.1B37% margin
Net income₹2.1B25.3% margin
Valuation
PER (trailing)33.3x
PER (forward)25.0x
P/Book5.8x
Beta0.63
Balance sheet & cash
Market cap₹69.8B
Total debt₹54.4M
Free Cash Flow₹335.3M
Debt / Equity0%
Profitability & ownership
ROE19.1%
ROA13.4%
% insiders71.3%
% institutions4.7%
Last declaration on 27 February 2024
Declarations8 total
  • ▲
    Executives
    0SEBI
    73,125 sharesEquity SharesSEBI:66f1ae6324dbf2535b430f6982b1b78a69651074
    Canonical exit: 26 May 2024 (T+90)
  • ▼
    Executives
    0SEBI
    73,125 sharesEquity SharesSEBI:f0e1be029b7d879395d7c21223084cdefbca9b14
  • ▲
    Executives
    2M INR5SEBI
    13,000 shares@ ₹190.220327.2% of flowEquity SharesSEBI:ad6317c156a07b97977355e156da8988abccf0b2
    Canonical exit: 29 Jun 2023 (T+90)
  • ▲
    Executives
    2M INR5SEBI
    14,000 shares@ ₹177.785627.5% of flowEquity SharesSEBI:0f45231f935e903d70d879d68ef9fd39893704fc
    Canonical exit: 27 Jun 2023 (T+90)
  • ▲
    Executives
    407,381 INR2SEBI
    2,000 shares@ ₹203.69054.6% of flowEquity SharesSEBI:7d0a1a2b3b4c7ab910c9d13ab8c99ad2846d5604
    Canonical exit: 1 Jun 2023 (T+90)
  • ▲
    Executives
    2M INR4SEBI
    8,000 shares@ ₹203.690818.4% of flowEquity SharesSEBI:942bd4b3d6b712c46ddee264e56a5ae9ebc64647
    Canonical exit: 1 Jun 2023 (T+90)
  • ▲
    Executives
    2M INR4SEBI
    8,000 shares@ ₹198.057517.8% of flowEquity SharesSEBI:61ccd40f30820cdc8d03ad416bdd010469cadc04
    Canonical exit: 29 May 2023 (T+90)
  • ▲
    Executives
    396,115 INR2SEBI
    2,000 shares@ ₹198.05754.5% of flowEquity SharesSEBI:ad17473ab9ff1ff8f679c082c9515d9b9e35d6b5
    Canonical exit: 29 May 2023 (T+90)

8 of 8 declarations

About Supriya Lifescience Limited

Supriya Lifescience Limited is a company engaged in the manufacturing of pharmaceutical products. It operates in the healthcare and pharmaceutical sector, listed on the Bombay Stock Exchange.